We are leveraging our industry-leading PDC technology platform, and focusing our resources on oncology therapeutics in areas of unmet medical and clinical need.
January 4, 2018
Cellectar Biosciences to Participate at Biotech Showcase 2018
December 14, 2017
Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers
Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers and cancer stem cells.